Anti-Coagulants - Japan

Japan

Highlights

In Japan, the Anti-Coagulants market is expected to see a significant increase in revenue.
According to projections, the revenue is estimated to reach US$1.39bn in 2024.
This growth is anticipated to continue, with an annual growth rate (CAGR 2024-2029) of 7.44%.
As a result, the market volume is projected to reach US$1.98bn by 2029.
When comparing the global market, United States is expected to generate the highest revenue in the Anti-Coagulants market.
In 2024, the revenue United States is estimated to be US$16.74bn.
Japan's aging population and high prevalence of atrial fibrillation are driving the demand for anti-coagulants in the country.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

Anti-coagulants are a crucial part of the pharmaceutical industry, with their demand increasing globally due to the rise in cardiovascular diseases. Japan, being one of the world's largest pharmaceutical markets, has witnessed a significant increase in the demand for anti-coagulants in recent years.

Customer preferences: Japanese consumers are highly health-conscious, which has led to an increase in demand for anti-coagulants. The aging population in Japan has also contributed to the surge in demand for these medicines. Furthermore, the preference for low molecular weight heparin (LMWH) over unfractionated heparin (UFH) has increased due to the lower risk of bleeding and ease of administration.

Trends in the market: The Japanese anti-coagulants market is expected to grow at a steady pace due to the rising prevalence of cardiovascular diseases and the aging population. The market is dominated by LMWH, which is expected to continue to grow in demand due to its ease of administration and lower risk of bleeding. Novel oral anticoagulants (NOACs) are also gaining popularity due to their improved safety profile and convenience compared to traditional anticoagulants.

Local special circumstances: The Japanese pharmaceutical market is highly regulated, and the approval process for new drugs can be lengthy and expensive. However, the Japanese government has been taking steps to streamline the approval process for new drugs, which could lead to more innovative anti-coagulants entering the market. Additionally, the Japanese healthcare system is shifting towards a more value-based system, which could lead to increased competition and cost-containment measures.

Underlying macroeconomic factors: The Japanese economy has been stagnant for several years, with low inflation and low interest rates. However, the government has been implementing policies to stimulate economic growth, which could lead to increased healthcare spending. Additionally, the aging population in Japan is expected to continue to drive demand for healthcare products and services, including anti-coagulants.In conclusion, the Japanese anti-coagulants market is expected to grow steadily in the coming years, driven by customer preferences for LMWH and NOACs, the aging population, and the Japanese government's efforts to streamline drug approvals and stimulate economic growth. However, the highly regulated pharmaceutical market and the shift towards a value-based healthcare system could pose challenges for companies operating in this market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.